We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.79% | 62.50 | 62.00 | 63.00 | 62.50 | 62.50 | 62.50 | 2,827 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.36 | 44.11M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/5/2016 06:38 | Bamboo2. You will do very well here in the long run. I see you have bought into QP as well.Did you manage to buy into QP in the low 60P's ? Thanks for posting the info. ATB. | callmebwana | |
21/5/2016 22:38 | Tissue Regenix Group plc, officially opens new Leeds site... | bamboo2 | |
20/5/2016 15:29 | results monday. | knights | |
18/5/2016 08:52 | Re, last weeks large share transaction. It does seem somewhat odd that we have not yet had a holdings RNS | bamboo2 | |
14/5/2016 09:50 | The German partnership should start producing income next year. I found this document, with a summary of the tie-up. | bamboo2 | |
11/5/2016 20:46 | Ballie Gifford & Co Ltd hold or maybe held about 5% | bamboo2 | |
11/5/2016 15:59 | Looks more like a sell to me. Why would it keep dribbling down on buys? Doesn't seem like optimism is rife here. Anyway, we need some news. | rayrac | |
11/5/2016 10:42 | That's near 5% of the company, so we'll soon find out from an RNS. | igbertsponk | |
11/5/2016 10:03 | Has Mr Woodford just added ?? 36,666,667 @18.5p - All the recent 18.5p's have been buys !! | channel pirate | |
06/5/2016 09:51 | Hmmm, the question is AndrewB, how much more is this going to dip !! I personally bought a few more at 19.25p when it dipped, but it looks like it is still dipping. Anyway, I still feel comfortable holding, especially as Mr W. was still buying recently at 20.25p | channel pirate | |
03/5/2016 11:10 | Close Asset Management sold 3.89 million prior to 4 April, leaving 3.47 million; so perhaps it's still selling; but others have been buying in the same period, so I don't feel there's a problem. Good time to take a position or picking up a few more on the dip. | andrewbaker | |
03/5/2016 09:22 | Regarding today's drop - maybe Mr Woodford has asked the mm's if they can gather a few more shares for him !! | channel pirate | |
26/4/2016 13:56 | The advert looks fine to me, I was able to follow it ok. Key to the product's success is the speed of cell migration and vascularisation of the graft. I'm not a doctor, but I understand the principles of wound healing. I think the advert will be easy for medical professionals to take in. | karmicpete | |
26/4/2016 06:15 | horneblower, it was part of the SAWC publicity. Presume directed at surgeons, clinicians and other woundcare profs. I know what you mean about the speed of the graphics but guess if you are familiar with the terminology, it's not a problem. TRX produce the best ECM's in the world. | bamboo2 | |
25/4/2016 21:12 | Hmm. Who is this directed at? How much did it cost? Why is some of the most important text flashed up too quick to be read? 'Fraid I'm not impressed. Hopefully the actual product is better than this ad. | horneblower | |
20/4/2016 06:51 | 20 April 2016 Tissue Regenix Group plc Notice of Preliminary Results Leeds, 20th April 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces that it will publish its unaudited preliminary results for the year ended 31(st) January 2016, on Monday 23(rd) May 2016. A results presentation will be held on the morning of the 23(rd) May in London, with corporate and financial updates from CEO Antony Odell, and CFO, Ian Jefferson, as well as guest speaker Dr Francisco da Costa from The Groups research partner, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil. | bamboo2 | |
15/4/2016 07:41 | SAWC on this week in the US. | bamboo2 | |
14/4/2016 11:55 | May not sound as desres but clearly more practical and fit for purpose. I'd be happy with a little retrace here to give me time to assemble some funds for another top up. | luminoso | |
14/4/2016 07:36 | luminoso, This move has happened over the last year or so. Ex Leeds Uni students who stay in the area will provide a useful pool of potential staff for the new labs. These are people who will have been taught by Eileen Ingham etc, so will have learnt the dCell process from the boss! 14 April 2016 Tissue Regenix Group plc Change of Registered Office Leeds, 14(th) April 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that the Company's Registered Office address has changed from The Biocentre, Innovation Way, Heslington, York, YO10 5NY to: Unit 1 & 2, Astley Way, Astley Lane Industrial Estate, Swillington, Leeds LS26 8XT with immediate effect. | bamboo2 | |
14/4/2016 07:21 | Moved from York to Leeds. New address does not have the ring of "Innovation Way"! | luminoso | |
10/4/2016 17:55 | Forms for Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament Still very few direct competitors, for Dermapure Most of these alternatives are not derived from dermis, but from amniotic, placental or other material. Some are from dermis, but are cryogenically preserved, meaning defrost hassle. Others look like they go beyond the description of minimal manipulation. | bamboo2 | |
06/4/2016 16:31 | Looks like we may have a 'proper'* Golden Cross on the chart in the next few days. *= 50sma crosses a rising 200sma. | bamboo2 | |
30/3/2016 22:12 | Later in the same meeting, Francisco da Costa was awarded the Jeffrey Borer Heart Valve Outcomes Abstract Award. | bamboo2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions